Navigation Links
New way to diagnose Alzheimer's disease promises earlier treatment
Date:9/17/2007

Physicians may be able to detect and treat Alzheimers Disease (AD) in its earliest stages, when patients are experiencing only mild degrees of cognitive impairment, thanks to new diagnostic criteria proposed by an international group of researchers.

Published in Lancet Neurology, the development of new guidelines was co-led by Dr. Howard Feldman, head of the Div. of Neurology in the University of British Columbias Faculty of Medicine. Feldman, who directs the Clinic for Alzheimers Disease and Related Disorders at Vancouver Coastal Health, co-authored the paper with French researcher Dr. Bruno Dubois and investigators from countries that include Japan, the U.S. and England. Feldman is a member of Vancouver Coastal Health Research Institute (VCHRI).

The proposed criteria are based on examining the structure and function of the brain using advanced brain imaging techniques as well as looking at spinal fluid for the imprint of the disease. Early detection will allow researchers to test vaccines that might be used preventively or to treat fully affected individuals, or other drug treatments that are directed at the earliest stages of the disease the best time to reduce symptoms.

Existing criteria, established in 1984, involve a two-step approach of evaluating functional disability and then looking for a cause, meaning diagnosis and treatment is delayed until patients have significant dementia symptoms. Integrating the profound neurobiological advances of the last 20 years allow for diagnoses based on more than declining functional ability, says Feldman, a senior investigator with the Brain Research Centre (BRC) at UBC Hospital. We now have advanced diagnostic tools distinctive and reliable biological indicators that can be detected before the patient crosses the dementia threshold of disability.

The new criteria the researchers are proposing to the scientific community via the article represent a significant shift and will direct scientists and clinicians to a different focus than has been pursued over the last decade, he adds.

New diagnostic measures include a clinical core of early, progressive and significant episodic memory loss plus one or more abnormal biomarkers (biological indicators) characteristic of AD, including atrophy (wasting) of the temporal lobe as shown on Magnetic Resonance Imaging; abnormal amyloid Beta protein concentrations in the cerebrospinal fluid; a specific pattern showing reduced glucose metabolism on Positron Emission Tomography scans of the brain; and a genetic mutation for AD within the immediate family.

AD is a neurodegenerative disease characterized by progressive cognitive deterioration and is the most common form of dementia. The Alzheimer Society of Canada estimates that the disease affects more than 238,000 Canadians and that by 2031 about 750,000 Canadians will suffer from AD and related dementias. Approximately $5.5 billion per year is spent caring for persons with AD and related dementias in Canada. The Alzheimers Association in the U.S. estimates there are approximately 500,000 Americans younger than 65 with Alzheimers or other dementia.

Validation studies are needed to further explore the criteria and improve their sensitivity, specificity and accuracy, say the researchers.


'/>"/>

Contact: Hilary Thomson
Hilary.thomson@ubc.ca
604-822-2644
University of British Columbia
Source:Eurekalert

Related medicine news :

1. How to diagnose heart failure?
2. Pain-Free Heart Attacks Often Misdiagnosed
3. New technique to diagnose heart disease
4. Blood test diagnoses heart failure in short time
5. Heart disease diagnosed by dentist?
6. A Simple Exercise Can Uncover Undiagnosed Asthma
7. Breast Cancer Diagnosed Late In Men
8. Imaging Modality That Might Help Diagnose Depression
9. Restless leg syndrome may remain under-diagnosed in many
10. Stroke In The Right-Brain Can Remain Undiagnosed
11. Eye Diseases Diagnosed Through Genetical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... In ... be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into ... this type of healthcare model in the diagnosis and treatment of brain tumors. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant ... website. , Rod has been at the forefront of Gardant since it was founded ... Rod has overseen the opening of more than 40 new senior living communities. With ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her ... good news for single women is that she put all the words in her ... 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... familiar. This makes it difficult for lab operators and management to assess these ... help them identify wasteful or unnecessary actions. , Created with the help ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: